Company: OSRH
Filing Date: 2025-05-28
Form Type: S-1
Source: 0001213900-25-048346
Chunk: 79

Company: OSR Holdings, Inc.
Filing Date: 2025-05-28
Form: S-1
Chunk 79
---
 $ of
wages and salaries, from Darnatein.

|                                       |     | (Unaudited) three months ended March 31, 
 2025                                     |          |   |     | 2024 |              |   |
|:--------------------------------------|:----|:-----------------------------------------|:---------|:--|:----|:-----|:-------------|:--|
| Total operating revenues              |     | $                                        | -        |   |     | $    | -            |   |
| Net loss attributable to OSR Holdings |     |                                          | (141,742 | ) |     |      | (751,979,471 | ) |

Pro forma data may not be indicative
of the results that would have been obtained had these events occurred at the beginning of the periods presented, nor is it intended to
be a projection of future results.

The acquisition-date fair value of Darnatein
was measured using the Discount Cash Flow (“DCF”) method and the Risk adjusted Net Present Value (“r-NPV”) method
by outside valuation professionals. Key estimations and assumptions used in measuring the fair value of Darnatein are as follows:

| ● | 19.88% of discount rate (Weighted Average Cost of Capital: WACC) used in discounting operating cashflows |

| ● | Patent technology will generate operating revenue for 20 years |

| (*1) | OSR ordinary shares issued for purchase consideration of $81,436,889 is 590,425 shares at $138 per share. The number of OSR ordinary shares to be issued was determined based on negotiation with former owners of Darnatein. |

53

Patent technology - Darnatein

Details of patent technology recognized from the acquisition
of Darnatein that occurred during the year ended December 31, 2023 are set forth in the table below.

| Patent technology project code: |     | Amount |            |
|:--------------------------------|:----|:-------|-----------:|
| DRT 101                         |     | $      | 73,513,419 |

DRT-101 is a synthetic bio-signaling
molecule that replaces BMPRII-binding segments of BMP-7, one of the bone-forming proteins, with high affinity ActRII binding segments
of Activin A, a member of the transforming growth factor β (TGF-β) superfamily along with BMP-7. In nature, endogenous BMP7
prom